Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm

Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of litigations and investigations came to haunt the giant. Yet, what makes Wells Fargo analyst David Maris dismiss market enthusiasm as overblown?

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts